News about Market

GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Adults Aged 60 and Above

China’s drug regulator has accepted GSK’s Arexvy for review to prevent RSV-related lower respiratory tract disease in adults 60 and older, with a decision expected in 2027.

Market | 11/02/2026 | By News Bureau |  223

Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement

Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.

Market | 11/02/2026 | By Darshana |  164

Pandorum Technologies Raises USD 18 Million in Series B to Advance Regenerative Therapies

Pandorum Technologies has raised USD 18 million in a Series B funding round to accelerate the clinical development and global market access of its programmable tissue regenerative therapies, with expansion plans spanning the US, Asia and the Middle East.

Market | 11/02/2026 | By News Bureau |  189

Waters Completes Merger with BD's Biosciences and Diagnostic Solutions Businesses

Waters has completed its merger with BD’s Biosciences and Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader focused on high-volume testing in regulated applications, alongside announcing the appointment of Claire M Fraser, PhD, to its Board and the formation of four new operating divisions.

Market | 10/02/2026 | By News Bureau |  215

Novartis Builds Global Biomedical Research Centre in San Diego

Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.

Market | 09/02/2026 | By News Bureau |  138

Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology

The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.

Market | 09/02/2026 | By News Bureau |  117

Breckenridge Pharmaceutical Partners with Medichem Solutions to Expand US Hospital Injectable Portfolio

Breckenridge Pharmaceutical enters a strategic collaboration with Medichem Solutions to supply injectable medicines for anaesthesia, critical care and emergency use, strengthening its presence in the US hospital segment.

Market | 07/02/2026 | By News Bureau |  162

Angitia Biopharmaceuticals Bags USD 130 Million in Series D Capital Raise

Angitia Biopharmaceuticals has raised USD 130 million in a Series D financing round co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners. The funds will be used to advance the clinical development of lead programmes AGA2118, AGA2115, AGA111 and other pipeline assets.

Market | 06/02/2026 | By News Bureau |  280

Insilico Medicine Receives USD 5 Million from Menarini

Insilico received an additional $5 million milestone from Menarini following first-in-patient dosing in a Phase I trial of MEN2501, a generative AI-designed KIF18A inhibitor for chromosomally unstable solid tumours.

Market | 05/02/2026 | By News Bureau |  163

Mankind Pharma Sees Margin Expansion, Chronic Segment Gains in Q3FY26

Mankind Pharma announced its consolidated financial results for the third quarter and nine months ended December 31, 2025, reporting steady growth driven by improved performance in its domestic pharmaceutical business and consolidation of its BSV portfolio.

Market | 04/02/2026 | By Darshana |  189